Cognetivity Neurosciences (CSE: CGN) continued to take the Middle East by storm this morning. The firm has continued its pattern of signing with health care providers in the region, this time signing with the largest healthcare network in the United Arab Emirates.
The company has entered into an agreement with Abu Dhabi Health Services Company, an independent company that owns and operates all of the public hospitals and clinics across Abu Dhabi. The agreement will see Cognetivity’s CognICA cognitive assessment tool utilized under a pilot program, whereby it will be used as a screening tool across the network for cognitive impairment and brain health.
The healthcare network currently boasts 13 hospitals within its network, along with 36 primary healthcare clinics and 24 supporting facilities. The agency conducts five million outpatient and 100,000 inpatient visits annually, while acting as a pioneer in terms of digitalization of its healthcare network.
Sponsored · Antimony Resources
“We’re hugely excited about this latest deployment of our CognICATM technology and thrilled to confirm another major deal in the Middle East. To tackle the enormous global problem of brain health, including dementia, we have to massively improve the detection of early-stage impairment on a large scale, making brain health testing as routine as blood pressure monitoring. CognICATM is the perfect tool in every way for this job and this latest implementation further demonstrates the value that our technology adds to progressive healthcare systems,” commented CEO Sina Habibi.
The launch of the pilot program is viewed as a “first step” for the rollout of the firms flagship product across the healthcare network. If the program is successful, its expected that a large scale rollout will occur, with the tech used for the timely diagnosis of mild cognitive impairment as well as dementia.
Cognetivity Neurosciences last traded at $0.34 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
